One of our patients from this past week has given us full permission to share her story with you. A year ago I would have called her an average patient but now that I have moved LipiFlow to my front line of therapeutic options, I would say that she is much worse than my average patient who chooses treatment before declining to this point.
While LipiFlow offers a dramatic change in my approach to patients with symptomatic evaporative dry eye, I want to fully disclose that I am:
a) compensated by Duke Medical Center for taking care of patients
b) compensated by TearScience as an adviser and consultant